doi: 10.1161/01.RES.0000185326.04010.9f
© 2005 American Heart Association, Inc.
Review |
Heart Valve Tissue Engineering
From The Saban Research Institute of Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California.
Correspondence to Ivan Vesely, PhD, The Saban Research Institute of Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, 4650 Sunset Blvd–MS137, Los Angeles, CA 90027. E-mail ivesely{at}chla.usc.edu
This Review is part of a thematic series on Cardiovascular Tissue Engineering, which includes the following articles:
Custom Design of the Cardiac Microenvironment With Biomaterials
Heart Valve Tissue Engineering
Engineering a Small-Diameter Artificial Artery
Engineering Myocardial Tissue
Regenerative Cardiomyocytes for Cardiovascular Tissue Engineering
Richard T. Lee Guest Editor
Tissue-engineered heart valves have been proposed by physicians and scientists alike to be the ultimate solution for treating valvular heart disease. Rather than replacing a diseased or defective native valve with a mechanical or animal tissue–derived artificial valve, a tissue-engineered valve would be a living organ, able to respond to growth and physiological forces in the same way that the native aortic valve does. Two main approaches have been attempted over the past 10 to 15 years: regeneration and repopulation. Regeneration involves the implantation of a resorbable matrix that is expected to remodel in vivo and yield a functional valve composed of the cells and connective tissue proteins of the patient. Repopulation involves implanting a whole porcine aortic valve that has been previously cleaned of all pig cells, leaving an intact, mechanically sound connective tissue matrix. The cells of the patients are expected to repopulate and revitalize the acellular matrix, creating living tissue that already has the complex microstructure necessary for proper function and durability. Regrettably, neither of the 2 approaches has fared well in animal experiments, and the only clinical experience with tissue-engineered valves resulted in a number of early failures and patient death. This article reviews the technological details of the 2 main approaches, their rationale, their strengths and weaknesses, and the likely mechanisms for their failure. Alternative approaches to valvular tissue engineering, as well as the role of industry in shaping this field in the future, are also reviewed.
Key Words: cardiac valves • tissue engineering • review • acellular matrix • scaffold
This article has been cited by other articles:
 |
|
 |
|
  F. J. Schoen Evolving Concepts of Cardiac Valve Dynamics: The Continuum of Development, Functional Structure, Pathobiology, and Tissue Engineering Circulation, October 28, 2008; 118(18): 1864 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mehta, R. E. Peterson, and W. Heideman 2,3,7,8-Tetrachlorodibenzo-p-dioxin Exposure Prevents Cardiac Valve Formation in Developing Zebrafish Toxicol. Sci., August 1, 2008; 104(2): 303 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]
|
|
|
|
 |
|
 L. Krishnan, J. B. Hoying, H. Nguyen, H. Song, and J. A. Weiss Interaction of angiogenic microvessels with the extracellular matrix Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3650 - H3658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Van Nooten, P. Somers, M. Cornelissen, S. Bouchez, F. Gasthuys, E. Cox, L. Sparks, and K. Narine Acellular porcine and kangaroo aortic valve scaffolds show more intense immune-mediated calcification than cross-linked Toronto SPV(R) valves in the sheep model Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 544 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vincentelli, F. Juthier, and B. Jude Reply to the editor. J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 737 - 737. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Dohmen and W. Konertz Results With Decellularized Xenografts Circ. Res., August 18, 2006; 99(4): e10 - e10. [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Zimmermann, M. Didie, S. Doker, I. Melnychenko, H. Naito, C. Rogge, M. Tiburcy, and T. Eschenhagen Heart muscle engineering: An update on cardiac muscle replacement therapy Cardiovasc Res, August 1, 2006; 71(3): 419 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cebotari, A. Lichtenberg, I. Tudorache, A. Hilfiker, H. Mertsching, R. Leyh, T. Breymann, K. Kallenbach, L. Maniuc, A. Batrinac, et al. Clinical Application of Tissue Engineered Human Heart Valves Using Autologous Progenitor Cells Circulation, July 4, 2006; 114(1_suppl): I-132 - I-137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lichtenberg, I. Tudorache, S. Cebotari, M. Suprunov, G. Tudorache, H. Goerler, J.-K. Park, D. Hilfiker-Kleiner, S. Ringes-Lichtenberg, M. Karck, et al. Preclinical Testing of Tissue-Engineered Heart Valves Re-Endothelialized Under Simulated Physiological Conditions Circulation, July 4, 2006; 114(1_suppl): I-559 - I-565. [Abstract] [Full Text] [PDF]
|
|